MP-06.01
Magnetic Resonance Imaging for Prostate Cancer: A Comparative Study Including Radical Prostatectomy Specimens
Liam Toner, Australia

MP-06.02
A Randomized Prospective Trial to Assess the Outcomes of MRI/TRUS-Guided Prostate Biopsy and Traditional 12-Core TRUS-Guided Prostate Biopsy
Eduard Baco, Norway

MP-06.03
Analysis of the Impact and Patterns of Care Surrounding TRUS Biopsy Sepsis
Elliot Anderson, Australia

MP-06.04
Repeat Biopsy Rates for Premalignant Lesions in a Statewide Quality Improvement Collaborative
Frank N. Burks, USA

MP-06.05
Do We Cure or Potentially Harm Patients with Prostate Cancer Diagnosed by Repeated Biopsies?
Roman Tomaskin, Slovakia

MP-06.06
Transperineal Template Biopsy for Prostate Cancer Detection after Negative Transrectal Biopsy: Does Ethnicity Matter?
Niyukta Thakare, UK

MP-06.07
The Role of 11C-Choline PET/CT in Diagnosing Prostate Cancer at Repeat Biopsy
Yijun Shen, China

MP-06.08
Multiparametric Magnetic Resonance Tomography and MRI/TRUS-Fusion Guided Biopsy for Index Lesion Detection and Localization: Correlation with Radical Prostatectomy Specimen
Boris A. Hadaschik, Germany

MP-06.10
Performance of Biopsy Factors in Predicting Unfavorable Disease in Patients Eligible for Active Surveillance According to the PRIAS Criteria
Giorgio Ivan Russo, Italy
MP-06.11  
Using Active Surveillance in Biopsy Proven Gleason 3+4 Prostate Cancer  
Lih-Ming Wong, Australia

MP-06.12  
Important Factors to Consider in Selection of Low Risk Prostate Cancer Patients for Active Surveillance  
Daniel Z P Yong, Singapore

MP-06.13  
Biochemical Recurrence Rates in Active Surveillance Candidates and the Role of Improving Gleason Grading  
Roderick van den Bergh, Australia

MP-06.14  
Pathological Upgrading in Prostate Cancer Patients Eligible for Active Surveillance: Does Prostate Specific Antigen Density Matter?  
Jae Shin Park, South Korea

MP-06.15  
Surgical Outcomes of South Australian Patients Who Have Discontinued Active Surveillance  
Sophie Plagakis, Australia

MP-06.16  
Increasing Rates of Active Surveillance: The Effect on Prostate Cancer Management and Surgical Outcomes  
Matthew Morey, Australia